Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy
Sernova received FDA Orphan Drug Designation for Autologous Islet Transplantation to prevent diabetes resulting from total pancreatectomy. The designation provides seven years of potential market exclusivity in the U.S. upon approval, along with tax credits and fee waivers for development.
Key figures
- Drug Name
- Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy
- Exclusivity years
- 7
- Patient threshold
- fewer than 200,000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.